ストックスクリーナーアプリを入手
0.515
6.35%
-0.0349
アフターアワーズ：
.51
-0.005
-0.97%
前日終値:
$0.5499
開ける：
$0.5381
24時間の取引高:
73,310
Relative Volume:
0.19
時価総額：
$7.50M
収益：
-
当期純損益:
$-15.42M
株価収益率:
-0.2799
EPS:
-1.84
ネットキャッシュフロー:
$-13.41M
1週間 パフォーマンス:
-27.77%
1か月 パフォーマンス:
-38.62%
6か月 パフォーマンス:
-56.36%
1年 パフォーマンス:
-77.61%
1日の値動き範囲:
$0.5101
$0.5499
1週間の範囲:
$0.5101
$0.70
52週間の値動き範囲:
$0.5101
$3.10
Indaptus Therapeutics Inc Stock (INDP) Company Profile
名前
Indaptus Therapeutics Inc
セクター
電話
(646) 427-2727
住所
3 COLUMBUS CIRCLE, NEW YORK
INDP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.515 | 7.50M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.36B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.95B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.13B | 3.81B | -644.79M | -669.77M | -6.24 |
Indaptus Therapeutics Inc (INDP) 最新ニュース
Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times
Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com
Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients - Marketscreener.com
Indaptus reports progress in Decoy20 cancer therapy trial - Investing.com India
Breakthrough: Indaptus Cancer Drug Successfully Activates Immune System in Weekly Dosing Trial - Stock Titan
Indaptus tests new cancer therapy combination By Investing.com - Investing.com Australia
Indaptus tests new cancer therapy combination - Investing.com India
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Groundbreaking Cancer Trial: Indaptus Combines Novel Decoy20 with Checkpoint Inhibitor - StockTitan
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Benzinga India
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Drop in Short Interest - Defense World
INDAPTUS THERAPEUTICS Earnings Results: $INDP Reports Quarterly Earnings - Nasdaq
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics reports full-year loss of $1.61 per share -March 13, 2025 at 07:40 am EDT - Marketscreener.com
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results - TradingView
Indaptus Therapeutics Enrolls Over 20 Patients in Phase 1 Trial of Decoy20, Achieving Key Clinical Milestone - Nasdaq
Indaptus Therapeutics, Inc. SEC 10-K Report - TradingView
Registration Is Now Open For Tribe Public’s Webinar Event - GlobeNewswire
Registration Is Now Open For Tribe Public's Webinar Event 'Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 - The Manila Times
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - GlobeNewswire
Registration Is Now Open For Tribe Public’s Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - Nasdaq
Indaptus Therapeutics extends patent portfolio in China, Japan, and Israel - BioSpectrum Asia
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments - Marketscreener.com
Indaptus secures new patents in Asia and Israel for Decoy platform By Investing.com - Investing.com South Africa
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - The Manila Times
Indaptus secures new patents in Asia and Israel for Decoy platform - Investing.com
Indaptus Therapeutics Secures New Patent Approvals in China, Japan, and Israel for Decoy Platform in HIV and HBV Treatment - Nasdaq
Can Indaptus' New Asian Patents Transform Its Position in the $4B Hepatitis B Market? - StockTitan
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - The Manila Times
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - StockTitan
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 0.6% – Should You Sell? - Defense World
Indaptus Therapeutics Enters Standby Equity Purchase Deal With YA II PN -February 12, 2025 at 12:30 pm EST - Marketscreener.com
Indaptus Therapeutics Enters Equity Purchase Agreement With Ya II Pn -February 12, 2025 at 09:29 am EST - Marketscreener.com
Indaptus Therapeutics expands cancer trial to Canada - Investing.com India
Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares - Marketscreener.com
Indaptus Therapeutics Expands Decoy20 Clinical Trial To Canada - Nasdaq
Indaptus Therapeutics expands cancer trial to Canada By Investing.com - Investing.com South Africa
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - The Manila Times
Major Clinical Trial Expansion: Indaptus' Cancer Immunotherapy Decoy20 Gets Canadian Green Light - StockTitan
Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World
Indaptus Therapeutics Receives Notification from Nasdaq Regarding Minimum Bid Price RequirementUnited States Securities and Exchange Commission, Washington, DC 20549Form 8-KIndaptus Therapeutics, Inc. recently received a notification from Nasda - Defense World
Indaptus Therapeutics Announces $2.25 Million Private Placement - Defense World
Indaptus Therapeutics Inc (INDP) 財務データ
収益
当期純利益
現金流量
EPS
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):